Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Primary Immune Deficiency Disorders (PIDD)

Drug Information

Target Indication

Primary Immune Deficiency Disorders (PIDD)

Clinical Trial

Last updated: 1/1/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ADMA

ADMA BIOLOGICS, INC.

Related Pipeline

Primary Immune Deficiency Disorder

Upper Respiratory Tract Infection